ImmuONE is building the diagnostic infrastructure for the lungs, turning every breath into data. While most biotechs chase cures, this UK-based startup is mastering the art of understanding immune response before toxicity strikes.

"They aren't just testing drugs—they're decoding the lung's immune language in a market where safety failures cost billions."

The team composition tells a story of deep science meeting commercial hustle. CEO Abigail Martin steers the ship while CSO Victoria Hutter (co-founder) anchors the science. Principal Lead Scientist Ewelina Hoffman and Lead Commercial Scientist Joanne Kelsall bridge the lab-to-market gap, with Louis Scott driving immunology partnerships. This isn't a scattered startup—it's a focused unit.

• Pulmonary toxicity is their moat—generalist CROs can't replicate their lung-specific models
• Zero traffic, high revenue ($3.7M) = pure B2B efficiency, no consumer fluff
• 24 employees, $3.38M funding = capital efficient, likely pre-Series A or early growth
• YouTube & LinkedIn only—social proof over SEO, clinical validation over clicks